
Many fail to recognize that estrogen is necessary to help your body and its parts work in concert with each other seamlessly.

Many fail to recognize that estrogen is necessary to help your body and its parts work in concert with each other seamlessly.

The FDA has granted fast track designation to ITM-94 as a diagnostic agent for the detection of the most common type of kidney cancer.

The FDA has approved Epkinly plus Revlimid and Rituxan for the treatment of patients with relapsed or refractory follicular lymphoma.

Steve Brown and Lisa Booth explain how AI platforms like CureWise offer clarity, reduce anxiety, and support informed decisions during the cancer journey.

I am thankful that a nurse navigator gave me continuity of compassionate care that helped me to heal from the inside out.

Young adults with newly diagnosed cancer may feel overwhelmed, but open communication with doctors and support groups can help them feel less alone.

Todd Kennedy, a multiple myeloma survivor, explains how switching from an hours-long IV infusion to a 3-minute Sub-Q injection changed his life.

A man nearing 76 reflects on aging, family, loss and living with cancer while finding gratitude in the holiday season.

For U.S. Marine Corps veteran and devout marathon runner Hank Donigan, not even a diagnosis of brain cancer could slow him down.

Patients with severe pancreatic cancer pain experienced consistent improvements in functionality and quality of life following targeted ablation therapy.

Dr. Joshua Sabai spoke with Dr. Chandler Park about the latest advances in kidney cancer, highlighting clinical trials that are shaping care for patients.

Learn about stage 2 vaginal cancer, including symptoms, diagnosis, treatment options, side effects and questions to discuss with your care team.

Stage 2 multiple myeloma can feel overwhelming. Learn what it means, treatment options, and key questions to discuss with your oncologist.

Breaking down the rare gastrointestinal cancer, from diagnosis to treatment.

This guide explains diagnosis, staging, treatment options, side effects and a patient’s metastatic experience with osteosarcoma.

A real-world study found TKIs were the most common therapy for adults with metastatic renal cell carcinoma after prior immune checkpoint inhibitor use.

A study at IKCS finds higher BMI after kidney cancer diagnosis improves survival, while significant weight loss predicts poorer outcomes.

LiveLung invites the Tampa area lung cancer community to its monthly educational meeting.

American Indian and Alaskan Native individuals face some of the highest kidney cancer burdens in the United States.

I want to appreciate and acknowledge the one person who has had a profoundly positive impact on me throughout my 16-year journey with chronic small lymphocytic lymphoma.

In honor of Lung Cancer Awareness Month, CURE spoke with Dr. Daniel J. Boffa about how the understanding of lung cancer is evolving beyond smoking.

FOG-001 received fast track designation after early study results showed tumor shrinkage in all evaluable patients with desmoid tumors.

Following the 2025 ESMO Congress, Dr. Joshua Saba sat down with Dr. Chandler Park to discuss recent advances in prostate cancer care.

A woman shares how vision loss led to her cancer diagnosis and how lifestyle changes, support and community helped her regain control after her cancer had spread.

Cindy and Katie share how caring for parents with cholangiocarcinoma led to friendship, support and advocacy through the Cholangiocarcinoma Foundation.

The FDA approved Poherdy as the first interchangeable biosimilar to Perjeta for patients with HER2-positive breast cancer.

As a breast cancer survivor, I try to stay up to date on new ways to detect cancer early. When I first heard about a simple blood test called Cancerguard, I sat up a little straighter.

The FDA has granted orphan drug designation to tinostamustine, an investigational therapeutic, for the treatment of patients with malignant gliomas.

The FDA approved Komzifti in relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.

Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data presented at the 2025 ESMO Congress.